Novo Nordisk A/S is acquiring Akero Therapeutics for $54 per share, totaling approximately $4.7 billion, to enhance its treatment portfolio for MASH, an obesity-related liver condition. This deal includes a contingent payment of $6 per share pending regulatory approval, and is expected to close by year-end 2025.